Bengt Hallberg
Avd-/Sektionschef, Inst
Avd för medicinsk kemi och-
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in
NSCLC
Abdulmalik Bokhari, Wei-Yun Lai, A. T. Le, Jonatan L. Gabre, Tzu-Po Chuang, Susanne Fransson, B. Bergman, Anna Djos, N. Chen, Tommy Martinsson, J. Van den Eynden, R. C. Doebele, Ruth H. Palmer, Bengt Hallberg, Ganesh Umapathy
Lung Cancer - 2022 -
Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase
Activation
D. Treis, Ganesh Umapathy, Susanne Fransson, Jikui Guan, Patricia Mendoza-García, Joachim T. Siaw, S. Wessman, L. G. Murkes, J. J. E. Stenman, Anna Djos, L. H. M. Elfman, J. I. Johnsen, Bengt Hallberg, Ruth H. Palmer, Tommy Martinsson, P. Kogner
JCO Precision Oncology - 2022 -
Loss of RET Promotes Mesenchymal Identity in Neuroblastoma
Cells
Joachim T. Siaw, Jonatan L. Gabre, Ezgi Uçkun, M. Vigny, W. C. Zhang, J. Van den Eynden, Bengt Hallberg, Ruth H. Palmer, Jikui Guan
Cancers - 2021 -
BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma
Cells
Ezgi Uçkun, Joachim T. Siaw, Jikui Guan, Vimala Anthonydhason, Johannes Fuchs, Georg Wolfstetter, Bengt Hallberg, Ruth H. Palmer
Journal of Molecular Biology - 2021 -
Chromosome imbalances in neuroblastoma—recent molecular insight into chromosome 1p-deletion, 2p-gain, and 11q-deletion identifies new friends and foes for the
future
Jikui Guan, Bengt Hallberg, Ruth H. Palmer
Cancers - 2021 -
ATR inhibition enables complete tumour regression in ALK-driven NB mouse
models
Joanna Szydzik, Dan Emil Lind, Badrul Arefin, Yeshwant Kurhe, Ganesh Umapathy, Joachim T. Siaw, A. Claeys, Jonatan L. Gabre, J. van den Eynden, Bengt Hallberg, Ruth H. Palmer
Nature Communications - 2021 -
Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell
migration
H. Huang, A. Gont, L. Kee, R. Dries, K. Pfeifer, B. Sharma, D. N. Debruyne, M. Harlow, S. Sengupta, Jikui Guan, C. M. Yeung, W. C. Wang, Bengt Hallberg, Ruth H. Palmer, M. S. Irwin, R. E. George
Cell Reports - 2021 -
Neuroblastoma xenograft models demonstrate the therapeutic potential of
Lu-177-octreotate
Arman Romiani, Johan Spetz, Emman Shubbar, Dan Emil Lind, Bengt Hallberg, Ruth H. Palmer, Eva Forssell-Aronsson
BMC Cancer - 2021 -
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK
mutation.
Marcus Borenäs, Ganesh Umapathy, Wei-Yun Lai, Dan Emil Lind, Barbara Witek, Jikui Guan, Patricia Mendoza-García, Tafheem Masudi, Arne Claeys, Tzu-Po Chuang, Abeer El Wakil, Badrul Arefin, Susanne Fransson, Jan Koster, Mathias Johansson, Jennie Gaarder, Jimmy Van den Eynden, Bengt Hallberg, Ruth H. Palmer
The EMBO journal - 2021 -
11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in
Neuroblastoma
Joachim T. Siaw, Niloufar Javanmardi, Jimmy Van den Eynden, Dan Emil Lind, Susanne Fransson, Angela Martinez-Monleon, Anna Djos, Rose-Marie Sjöberg, Malin Östensson, H. Caren, G. Troen, K. Beiske, A. P. Berbegall, R. Noguera, Wei-Yun Lai, P. Kogner, Ruth H. Palmer, Bengt Hallberg, Tommy Martinsson
Cell Reports - 2020 -
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUG alpha) in neuroblastoma patient samples with chromosome arm 2p
rearrangements
Niloufar Javanmardi, Susanne Fransson, Anna Djos, Ganesh Umapathy, Malin Östensson, J. Milosevic, Marcus Borenäs, Bengt Hallberg, P. Kogner, Tommy Martinsson, Ruth H. Palmer
Genes Chromosomes & Cancer - 2020 -
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma
cells.
Diana Lizeth Cervantes-Madrid, Joanna Szydzik, Marcus Borenäs, Mats Bemark, Jean Cui, Ruth H. Palmer, Bengt Hallberg
Scientific reports - 2019 -
13P - Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic
pathways
Ganesh Umapathy, Jimmy Van den Eynden, Diana Lizeth Cervantes-Madrid, Joanna Szydzik, Jikui Guan, Ruth H. Palmer, Bengt Hallberg
Annals of oncology : official journal of the European Society for Medical Oncology. Vol. 30, Suppl. 1, p. i6 - 2019 -
Targeting anaplastic lymphoma kinase in
neuroblastoma
Ganesh Umapathy, Patricia Mendoza, Bengt Hallberg, Ruth H. Palmer
APMIS - 2019 -
Radiolabeled somatostatin analogue binding and internalization in human tumor cell
lines
Sofia Saadati, Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer, Bengt Hallberg, Khalil Helou, Eva Forssell-Aronsson
Gothenburg Cancer Meeting 2019, Gothenburg, Sweden - 2019 -
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor
ceritinib.
Jikui Guan, Susanne Fransson, Joachim T. Siaw, Diana Treis, Jimmy Van den Eynden, Damini Chand, Ganesh Umapathy, Kristina Ruuth, Alia Shamikh, Hans Jacobsson, Lena Gordon, Par-Johan Svensson, Magnus Hansson, Tommy Martinsson, Per Kogner, Ruth H. Palmer, Bengt Hallberg
Cold Spring Harbor molecular case studies - 2018 -
Molecular targeting of various human tumor cell lines with
177Lu-octreotate
Sofia Saadati, Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer, Bengt Hallberg, Khalil Helou, Eva Forssell-Aronsson
Annual Congress of the European Association of Nuclear Medicine October 13 - 17, 2018 Düsseldorf, Germany - 2018 -
Better therapeutic results after fractionated administration of Lu-177-octreotate in mice bearing human
neuroblastoma
Arman Romiani, Johan Spetz, Emman Shubbar, Ruth H. Palmer, Bengt Hallberg, Eva Forssell-Aronsson
The European Association of Nuclear Medicine (EANM) - 2018 -
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic
pathways.
Jimmy Van den Eynden, Ganesh Umapathy, Arghavan Ashouri, Diana Lizeth Cervantes-Madrid, Joanna Szydzik, Kristina Ruuth, Jan Koster, Erik Larsson, Jikui Guan, Ruth H. Palmer, Bengt Hallberg
Science signaling - 2018 -
In vitro screening for Lu-177-octreotate uptake in human tumor cell
lines
Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer, Bengt Hallberg, Khalil Helou, Eva Forssell-Aronsson
Cancerfondens Planeringsgrupp för Onkologisk Radionuklidterapi höstmöte 2017 - 2017 -
Therapeutic potential of Lu-177-octreotate for neuroblastoma – preclinical
studies
Arman Romiani, Johan Spetz, Emil Schüler, Haiying Wang, Ruth H. Palmer, Bengt Hallberg, Eva Forssell-Aronsson
NOPHO 35th Annual meeting 2017 19 - 23 May, Stockholm, Sweden - 2017 -
MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted
neuroblastomas.
Ganesh Umapathy, Jikui Guan, Dan Gustafsson, Niloufar Javanmardi, Diana Lizeth Cervantes-Madrid, Anna Djos, Tommy Martinsson, Ruth H. Palmer, Bengt Hallberg
Science signaling - 2017 -
Novel Mechanisms of ALK Activation Revealed by Analysis of the Y1278S Neuroblastoma
Mutation.
Jikui Guan, Yasuo Yamazaki, Damini Chand, Jesper R van Dijk, Kristina Ruuth, Ruth H. Palmer, Bengt Hallberg
Cancers - 2017 -
Dose-response study of Lu-177-octreotate in nude mice bearing human
neuroblastoma
Arman Romiani, Johan Spetz, Ruth H. Palmer, Bengt Hallberg, Eva Forssell-Aronsson
63rd Annual Meeting of the Radiation Research Society, Cancun, Mexico - 2017 -
Binding and internalization of 177Lu-octreotate in human tumor cell lines of different
origin
Sofia Saadati, Johan Spetz, Viktor Sandblom, Emil Schüler, Ruth H. Palmer, Bengt Hallberg, Khalil Helou, Eva Forssell-Aronsson
63rd Annual Meeting of the Radiation Research Society, Cancun, Mexico - 2017 -
Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not
ligand-independent.
Jikui Guan, Georg Wolfstetter, Joachim T. Siaw, Damini Chand, Fredrik Hugosson, Ruth H. Palmer, Bengt Hallberg
Oncotarget - 2017 -
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and
MYCN
Jikui Guan, E. R. Tucker, Haiying Wang, Damini Chand, L. S. Danielson, Kristina Ruuth, Abeer El Wakil, Barbara Witek, Y. Jamin, Ganesh Umapathy, S. P. Robinson, T. W. Johnson, T. Smeal, Tommy Martinsson, L. Chesler, Ruth H. Palmer, Bengt Hallberg
DMM Disease Models and Mechanisms - 2016 -
The role of the ALK receptor in cancer
biology
Bengt Hallberg, Ruth H. Palmer
Annals of Oncology - 2016 -
The potential of Lu-177-octreotate as a therapeutic alternative for metastatic
neuroblastoma
Arman Romiani, Johan Spetz, Emil Schüler, Wan Haiying, Ruth H. Palmer, Bengt Hallberg, Eva Forssell-Aronsson
62nd Annual International Meeting Radiation Research Society, Waikoloa, HI, USA, October 16-19, 2016 - 2016 -
Biodistribution of Lu-177-octreotate in nude mice with human neuroblastoma
tumors
Arman Romiani, Johan Spetz, Emil Schüler, Wan Haiying, Ruth H. Palmer, Bengt Hallberg, Eva Forssell-Aronsson
The 4th Swedish Cancer Research Meeting, Gothenburg, Sweden, November 7-8, 2016 - 2016 -
Comparative in vivo study of the biodistribution of Lu-177-octreotate in three neuroblastoma cell
lines
Arman Romiani, Johan Spetz, Emil Schüler, Wan Haiying, Ruth H. Palmer, Bengt Hallberg, Eva Forssell-Aronsson
The Swedish Cancer Society’s planning group for Oncological Radiotherapy, Uppsala, Sweden, November 24-25, 2016 - 2016 -
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and
mice
Joachim T. Siaw, Haiying Wang, Kathrin Pfeifer, V. M. Rivera, Jikui Guan, Ruth H. Palmer, Bengt Hallberg
Oncotarget - 2016 -
PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to
imatinib
F. A. Arts, Damini Chand, C. Pecquet, A. I. Velghe, S. Constantinescu, Bengt Hallberg, J. B. Demoulin
Oncogene - 2016 -
Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism of ALK activation in neuroblastoma
tumors.
Susanne Fransson, Magnus Hansson, Kristina Ruuth, Anna Djos, Ana Berbegall, Niloufar Javanmardi, Jonas Abrahamsson, Ruth H. Palmer, Rosa Noguera, Bengt Hallberg, Per Kogner, Tommy Martinsson
Genes, chromosomes & cancer - 2015 -
Binding and internalization of Lu-177-octreotate in two neuroblastoma cell lines and initial biodistribution studies in
animals
Arman Romiani, Johan Spetz, Emil Schüler, Wan Haiying, Ruth H. Palmer, Bengt Hallberg, Eva Forssell-Aronsson
Cancerfondens planeringsgrupp för onkologisk radionuklidterapi, Höstmöte, Linköping, Sweden, November 25-27, 2015 - 2015 -
Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic
Hypogonadism
Barbara Witek, A. El Wakil, C. Nord, U. Ahlgren, M. Eriksson, E. Vernersson-Lindahl, A. Helland, O. A. Alexeyev, Bengt Hallberg, Ruth H. Palmer
Plos One - 2015 -
The ALK receptor
family
Ruth H. Palmer, Bengt Hallberg
Receptor Tyrosine Kinases: Family and Subfamilies - 2015 -
FAM150A and FAM150B are activating ligands for Anaplastic Lymphoma
Kinase.
Jikui Guan, Ganesh Umapathy, Yasuo Yamazaki, Georg Wolfstetter, Patricia Mendoza, Kathrin Pfeifer, Ateequrrahman Mohammed, Fredrik Hugosson, Hongbing Zhang, Amy W Hsu, Robert Halenbeck, Bengt Hallberg, Ruth H. Palmer
eLife - 2015 -
The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in
neuroblastoma
Ganesh Umapathy, A. El Wakil, Barbara Witek, L. Chesler, L. Danielson, X. M. Deng, N. S. Gray, M. Johansson, S. Kvarnbrink, K. Ruuth, C. Schonherr, Ruth H. Palmer, Bengt Hallberg
Science Signaling - 2014 -
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in
neuroblastoma.
Damini Chand, Yasuo Yamazaki, Kristina Ruuth, Christina Schönherr, Tommy Martinsson, Per Kogner, Edward F Attiyeh, John Maris, Olena Morozova, Marco A Marra, Miki Ohira, Akira Nakagawara, Per-Erik Sandström, Ruth Palmer, Bengt Hallberg
Disease models & mechanisms - 2013 -
Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma
cells
K. Sattu, F. Hochgrafe, J. Wu, G. Umapathy, C. Schonherr, K. Ruuth, Damini Chand, Barbara Witek, J. Fuchs, P. K. Li, F. Hugosson, R. J. Daly, R. H. Palmer, Bengt Hallberg
Febs Journal - 2013 -
Jeb/Alk signalling regulates the Lame duck GLI family transcription factor in the Drosophila visceral
mesoderm
D. Popichenko, F. Hugosson, C. Sjogren, M. Dogru, Y. Yamazaki, Georg Wolfstetter, C. Schonherr, M. Fallah, Bengt Hallberg, H. Nguyen, R. H. Palmer
Development - 2013 -
Goliath family E3 ligases regulate the recycling endosome pathway via VAMP3
ubiquitylation
Y. Yamazaki, C. Schonherr, G. K. Varshney, M. Dogru, Bengt Hallberg, R. H. Palmer
Embo Journal - 2013 -
Mechanistic insight into ALK receptor tyrosine kinase in human cancer
biology
Bengt Hallberg, R. H. Palmer
Nature Reviews Cancer - 2013 -
Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies
Treatment
P. Mazot, A. Cazes, F. Dingli, J. Degoutin, T. Irinopoulou, M. C. Boutterin, B. Lombard, D. Loew, Bengt Hallberg, R. H. Palmer, O. Delattre, I. Janoueix-Lerosey, M. Vigny
Plos One - 2012 -
The ALK(F1174L) Mutation Potentiates the Oncogenic Activity of MYCN in
Neuroblastoma
T. Berry, W. Luther, N. Bhatnagar, Y. Jamin, E. Poon, T. Sanda, D. Pei, B. Sharma, W. R. Vetharoy, L. Moreau, Bengt Hallberg
Cancer Cell - 2012 -
Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to
therapy.
Tommy Martinsson, Therese Eriksson, Jonas Abrahamsson, Helena Carén, Magnus Hansson, Per Kogner, Sattu Kamaraj, Christina Schönherr, Joel Weinmar, Kristina Ruuth, Ruth H Palmer, Bengt Hallberg
Cancer research - 2011 -
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and
NVP-TAE684
C. Schonherr, K. Ruuth, Y. Yamazaki, T. Eriksson, J. Christensen, R. H. Palmer, Bengt Hallberg
Biochemical Journal - 2011